title: Current race in the development of DAAs (direct-acting antivirals) against HCV.
abstract: The direct-acting antivirals (DAAs) currently in development for treatment of hepatitis C fall into four categories: (i) NS3/4A protease inhibitors: ABT-450/r, faldaprevir, asunaprevir, GS-9256, vedroprevir (GS-9451), danoprevir, MK-5172, vaniprevir, sovaprevir, ACH-2684, narlaprevir and simeprevir, in addition to those that are already developed [telaprevir (Incivek®) and boceprevir (Victrelis®)], (ii) NS5A protein inhibitors: ABT-267, daclatasvir, ledipasvir, ACH-2928, ACH-3102, PPI-668, AZD-7295, MK-8742, and GSK 2336805; (iii) NS5B (nucleoside-type) polymerase inhibitors: sofosbuvir (now approved by the FDA since 6 December 2013), GS-0938, mericitabine, VX-135, ALS 2158 and TMC 649128; (iv) NS5B (non-nucleoside-type) polymerase inhibitors: VX-222, ABT-072, ABT-333, deleobuvir, tegobuvir, setrobuvir, VCH-916, VCH-759, BMS-791325 and TMC-647055. Future drug combinations will likely exist of two or more DAAs belonging to any of the 4 categories, with the aim to achieve (i) pan-genotypic hepatitis C virus (HCV) activity, (ii) little or no risk for resistance; (iii) short duration (i.e. 12 weeks) of treatment, and (iv) a sustained viral response (SVR) and definite cure of the disease.
authors.affiliation: Rega Institute for Medical Research, KU Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium. Electronic address: erik.declercq@rega.kuleuven.be.
authors.forename: Erik
authors.initials: E
authors.lastname: De Clercq
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D055808:Drug Discovery; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D016174:Hepacivirus / Q000187:drug effects* / Q000201:enzymology; D006526:Hepatitis C / Q000188:drug therapy / Q000821:virology; D006801:Humans; D058990:Molecular Targeted Therapy; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors*
chemical_list: D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D017361:Viral Nonstructural Proteins
keywords: Asunaprevir (PubChem CID: 16076883); Boceprevir (PubChem CID: 10324367); Daclatasvir (PubChem CID: 25154714); Danoprevir (PubChem CID: 71301228); Deleobuvir (PubChem CID: 56948249); Direct-acting antivirals; Faldaprevir (PubChem CID: 71300931); Hepatitis C virus (HCV); Ledipasvir (PubChem CID: 67505836); Mericitabine (PubChem CID: 16122663); NS3/4A protease inhibitors; NS5A protein inhibitors; NS5B (non-nucleoside-type) polymerase inhibitors; NS5B (nucleoside-type) polymerase inhibitors; Narlaprevir (PubChem CID: 11857239); Neceprevir (PubChem CID: 71301413); Setrobuvir (PubChem CID: 45136829); Simeprevir (PubChem CID: 24873435); Sofosbuvir (PubChem CID: 45375808); Sovaprevir (PubChem CID: 53362096); Tegobuvir (PubChem CID: 23649154); Telaprevir (PubChem CID: 3010818); Vaniprevir (PubChem CID: 24765256); Vedroprevir (PubChem CID: 25167947)